DF749F48-6A86-4640-9C62-31B4A7C5D1A9
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- G2M_CHECKPOINT+0.651
- E2F_TARGETS+0.641
- MYC_TARGETS_V1+0.574
- WNT_BETA_CATENIN_SIGNALING+0.446
- DNA_REPAIR+0.435
- NOTCH_SIGNALING+0.432
- MYC_TARGETS_V2+0.424
- MITOTIC_SPINDLE+0.407
- UNFOLDED_PROTEIN_RESPONSE+0.397
- TGF_BETA_SIGNALING+0.351
Top 10 suppressed
- MYOGENESIS-0.403
- INFLAMMATORY_RESPONSE-0.378
- IL6_JAK_STAT3_SIGNALING-0.350
- KRAS_SIGNALING_UP-0.323
- ALLOGRAFT_REJECTION-0.320
- COMPLEMENT-0.318
- COAGULATION-0.317
- XENOBIOTIC_METABOLISM-0.317
- INTERFERON_GAMMA_RESPONSE-0.285
- INTERFERON_ALPHA_RESPONSE-0.275
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_Z7890YNR | EPN | Supratentorial EPN | 0.914 |
| 2 | BS_Z7890YNR | Supratentorial Ependymoma | — | 0.901 |
| 3 | DD5AA3F8-E3EE-4EDD-8152-B1CC07B70A08 | — | — | 0.885 |
| 4 | BS_DS438CXE | high-grade glioma | — | 0.873 |
| 5 | TCGA-21-5783-01A-41R-2187-07 | — | cohortMD1 | 0.872 |
| 6 | SRR650181 | — | — | 0.867 |
| 7 | A3153235-3128-40AC-9371-AFA1F61E3E59 | — | — | 0.867 |
| 8 | C635C019-A66D-42B7-911C-4D0742CAF95A | — | — | 0.865 |
| 9 | MNG1000 | — | — | 0.862 |
| 10 | ERR2598180 | fetal | fetal | 0.862 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| G2M_CHECKPOINT | 0.651 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.641 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.574 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.446 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.435 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.432 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.424 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.407 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.397 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.351 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.267 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.231 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.221 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.199 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.153 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.152 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.146 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.128 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.127 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.124 | Idelalisib | — uncovered |